Drug Information

Drug General Information
Drug ID
D04VWJ
Former ID
DCL000053
Drug Name
ARRY-520
Drug Type
Small molecular drug
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 2 [524532]
Therapeutic Class
Anticancer Agents
Company
Array BioPharma.
Formula
C20H22F2N4O2S
Canonical SMILES
CN(C(=O)N1C(SC(=N1)C2=C(C=CC(=C2)F)F)(CCCN)C3=CC=CC=C3)<br />OC
InChI
1S/C20H22F2N4O2S/c1-25(28-2)19(27)26-20(11-6-12-23,14-7-4-3-5-8-14)29-18(24-26)16-13-15(21)9-10-17(16)22/h3-5,7-10,13H,6,11-12,23H2,1-2H3/t20-/m0/s1
InChIKey
LLXISKGBWFTGEI-FQEVSTJZSA-N
PubChem Compound ID
44224257
PubChem Substance ID
85240789, 89972591, 135298841, 135727852, 136340256, 136367488, 144241227, 152258638, 160647473, 162038121, 164138600, 164160768, 172650530, 174531203, 185998833, 196409584, 198950022, 226700217, 252477693
Target and Pathway
Target(s) Kinesin-like protein KIF11 Target Info Inhibitor [536588], [537357]
Reactome MHC class II antigen presentation
Kinesins
WikiPathways MHC class II antigen presentation
Kinesins
References
Ref 524532ClinicalTrials.gov (NCT01989325) A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma. U.S. National Institutes of Health.
Ref 536588Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Nov;29(9):625-55.
Ref 537357Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. Leukemia. 2009 May 21.